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Abstract
Introduction: The risk of cardiovascular disease (CVD) and atherosclerosis is reported to be increased in systemic
lupus erythematosus (SLE). We recently reported a negative association between natural IgM-antibodies against
phosphorylcholine (anti-PC) in the general population, high anti-PC levels leading to decreased atherosclerosis
development and low levels to increased risk of CVD. Potential mechanisms include anti-inflammatory properties
and inhibition of uptake of oxidized low density lipoprotein (LDL) in macrophages. The objective herein was to
study atherosclerosis in SLE in detail and in relation to traditional and non-traditional risk factors.
Methods: A total of 114 patients with SLE were compared with 122 age- and sex-matched population-based
controls. Common carotid intima-media thickness (IMT), calculated intima-media area (cIMa) and plaque occurrence
were determined by B-mode ultrasound as a surrogate measure of atherosclerosis. Plaques were graded according
to echogenicity and grouped as 1 to 4, with 1 being echoluscent, and considered most vulnerable. Anti-PC was
studied by ELISA.
Results: Hypertension, triglycerides and insulin resistance (determined by homeostasis model assessment of insulin
resistance) and C-reactive protein (CRP) were increased in SLE (P < 0.01) while smoking, LDL, high density
lipoprotein (HDL) did not differ between groups. Low levels of anti-PC IgM (lowest tertile) were more common in
SLE patients than in controls (P = 0.0022). IMT and cIMa did not differ significantly between groups. However,
plaques were more often found in SLE patients (P = 0.029). Age, LDL and IgM anti-PC (lowest tertile) were
independently associated with plaque occurrence in SLE. Further, in the left carotid arteries echoluscent plaques
(grade 1) were more prevalent in SLE as compared to controls (P < 0.016).
Conclusions: Plaque occurrence in the carotid arteries is increased in SLE and is independently associated with
age, LDL and low anti-PC levels. Vulnerable plaques were more common in SLE. Anti-PC could be a novel risk
marker also with a therapeutic potential in SLE.
Introduction
Early studies suggested that there is a bimodal pattern in
SLE, with manifestations including nephritis occurring
early and cardiovascular disease (CVD) later in life [1].
Several case-control studies indicate that atherosclerosis
is increased in SLE [2-5]. It has ever since become clear
that the risk of CVD is increased in SLE [6], which is a
clinical problem and also theoretically interesting since
atherosclerosis, the major cause of CVD, largely can be
considered an inflammatory disease where the immune
system may play an important role [7]. Activated macro-
phages and T cells producing inflammatory cytokines
are present in the atherosclerotic lesions [8]. Oxidized
low density lipoprotein (oxLDL) may play a major role
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any medium, provided the original work is properly cited.in atherosclerosis, constituting much of the lipid moiety
present in lesions. In addition, oxLDL has immune sti-
mulatory and pro-inflammatory properties [9,10]. The
pro-inflammatory effects of oxLDL may be caused by
inflammatory phospholipids with platelet activating fac-
tor (PAF)-like properties where phosphorylcholine (PC)
plays a major role in binding to the PAF-receptor
[11,12]. We recently demonstrated that natural IgM
antibodies against PC (anti-PC) are negatively associated
with atherosclerosis development in humans [13]
and that low levels of anti-PC predict increased CVD
risk [14-17]. Further, we reported that anti-PC were
decreased in a nested case-control SLE study and that
anti-PC has anti-inflammatory effects relevant in both
atherosclerosis and SLE, inhibiting the effects of an
inflammatory phospholipid, PAF [17], which is increased
in active SLE [18].
Thus, a combination of traditional and non-traditional
risk factors may account for the high prevalence of
CVD in SLE including dyslipemia, hypertension, oxLDL,
anti-phospholipid antibodies (aPL) and raised activity of
inflammatory factors like TNF and PAF-acetylhydrolase
(LDL-PLA2), C-reactive protein (CRP) [5,19-22].
We here report that atherosclerotic plaques are more
common and of potentially lower stability in SLE
patients as compared to controls and that among other
factors, atheroprotective anti-PC are implicated. The
implications of these findings are discussed.
Materials and methods
Study group
The study group consisted of 114 patients from Karo-
linska University Hospital Huddinge with diagnosed SLE
and 122 sex- and age-matched population-based con-
trols. Altogether, 160 patients younger than 70 years
with SLE were identified in the year 2006 through a
careful survey of patient journals of all patients admitted
to Huddinge Hospital for suspect SLE or SLE. Of these,
122 initially, but finally only 118, agreed to participate
and were included in our study which was named SLE-
VIC (SLE Vascular Impact Cohort) study. One hundred
twenty-two age- and sex-matched controls (recruited
randomly from Huddinge catchment area) were
accepted to participate. The inclusion was initiated in
August 2006 and ended in December 2007. Four
patients more where excluded because they did not fulfil
the American College of Rheumatology (ACR) criteria.
Of these 114 patients, three missed the ultrasound
investigation of carotids. Finally, our study consisted of
data for 114 patients fulfilling the 1982 revised criteria
of the ACR for SLE and 122 sex- and age-matched con-
trols. The study was approved by the Karolinska Insti-
tute research ethics committee and is in accordance
with the Helsinki Declaration. All subjects gave
informed consent before entering the study.
Study protocol
The investigation included a written questionnaire, an
interview, and a physical examination by a rheumatolo-
gist, laboratory determinations, and ultrasound examina-
tion of the carotid arteries. SLE activity was determined
with the Systemic Lupus Activity Measure (SLAM) and
also with Systemic Lupus Erythematosus diseases activ-
ity index (SLEDAI). Organ damage was determined with
Systemic Lupus International Collaborating Clinics
(SLICC) damage index.
Assays
Blood samples were collected between 07.30 and 10.00 h
after an overnight fast. The biochemical variables were
determined by standard laboratory methods. Serum and
cells were separately prepared in the laboratory before
storage at -80°C.
Immunological analyses of anticardiolipin antibodies
(aCL) and beta-2-glycoprotein antibodies were run by
the Karolinska Immune lab, Solna by an enzyme-linked
immunosorbent assay (ELISA). Lupus anticoagulans was
determined using nefelometri.
Anti-PC IgM was determined by use of a commercial
kit (Athera CVDefine-TM, Stockholm, Sweden) as
described by the manufacturers. Anti-PC IgG was deter-
m i n e db yu s eo ft h eC V D e f i n ek i t ,b u tt h es e c o n d a r y
antibody was switched to detect IgG (HRP-goat anti-
Human IgG, Invitrogen, Sweden).
Insulin resistance was assessed by calculating the
homeostasis model assessment of insulin resistance
(HOMA_IR) using the formula fasting insulin (μU/ml)
*fasting glucose (mmol/L)/22.5
Carotid B-mode ultrasonography
The right and left carotid arteries were examined with a
duplex scanner (Sequoia, Siemens Acuson, Mountain
View, Ca, USA) using a 6 MHz linear array transducer.
The patients were investigated in the supine position
with the head slightly turned from the sonographer.
Two trained sonographers performed all scans. The car-
otid arteries were carefully examined with regard to wall
changes. The far wall of the common carotid artery
(CCA), 0.5 to 1.0 cm proximal to the beginning of the
carotid bulb, was used for measurements of the intima-
media thickness (IMT). The IMT was defined as the dis-
tance between the leading edge of the lumen-intima
echo and the leading edge of the media-adventitia echo.
The CCA lumen diameter was defined as the distance
between the leading edge of the intima-lumen echo of
the near wall and the leading edge of the lumen-intima
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stored for subsequent analyses by a computer system
[23] with automated tracing of echo interfaces and mea-
surements of distances between the wall echoes within a
10 mm long section of CCA in late diastole, defined by
a simultaneous electrocardiographic recording. The
mean values of the IMT and lumen diameter within the
10 mm long section were calculated. When a plaque
was observed in the region of the CCA measurements,
the IMT was not measured.
Carotid plaque was defined as a localized intima-
media thickening of greater than 1 mm and at least a
100% increase in thickness compared with adjacent wall
segments. Plaque was screened for in the common,
internal and external carotid arteries. Plaque occurrence
was scored as the absence of plaque, the presence of
unilateral plaque, and the presence of bilateral plaque.
Plaque morphology in terms of echogenicity was
assessed in a modified version of the classification pro-
posed by Gray-Weale et al. [24] and graded from 1 to 4
as echolucent, predominantly echolucent, predominantly
echogenic and echogenic. Echolucency was defined with
the arterial lumen as reference and echogenicity with
the far wall adventitia as reference.
The differences between repeated measurements of
IMT and lumen diameter, by using the automated ana-
lyzing system, were 4.9% and 2.4% (coefficient of varia-
tion), respectively (with an IMT of 0.44 to 1.02 mm and
a lumen diameter of 4.38 to 7.9 mm). To compensate
for the stretching effect of arterial distension (secondary
to increased arterial pressure) on the wall thickness, the
cross-sectional intima-media area was calculated by
using the formula 3.14 ((lumen diameter/2 + intima-
media thickness)
2 - (lumen diameter/2)
2). This calcu-
lated intima-media area (cIMa), but not the IMT, has
been shown to be unaffected by variations in artery dis-
tension secondary to changes in blood pressure [25].
The ultrasonographic methods used have been described
in detail previously [26,27]. Repeated classification of
plaque morphology showed a correlation coefficient of
0.7 (P < 0.05) between the first and second classification
(n = 50).
Anthropometrical assessments
Body mass index (BMI) was calculated from weight/
height
2 (kg/m
2). Waist circumference (WC) was mea-
sured to the nearest 0.5 cm midway between the iliac
crest and the lower rib margin. Hip circumference (HC)
was measured in the horizontal plane around the sym-
physis pubis.
Statistical methods
Determinations were dichotomized or determined as
continuous variables as indicated. We calculated
percentiles based on distributions in the whole study
group. Age, gender and geography were matched for by
the design of the study. Data are presented as means
(with 95% confidence intervals, CI) or medians (with
interquartile ranges, IQR) depending on their distribu-
tion. Comparisons between groups were made with the
Mann-Whitney U-test, median test or Student’s t-test.
In order to establish the association between potential
risk factors for atherosclerosis and atherosclerotic pla-
que logistic regression was applied with adjustment for
covariates. SAS was used for the statistical analyses
(release 9.1, SAS Institute Inc., Cary, NC, USA).
Results
The characteristics of patients and controls are pre-
sented in Table 1. Major differences between cases and
controls include increased prevalence of: hypertension
(P < 0.001), defined as blood pressure ≥ 140/90 and/or
treatment against hypertension. Further, in SLE we
determined decreased levels of LDL (P = 0.026) and
increased levels of TG (P =0 . 0 0 3 ) ,C R P( P <0 . 0 0 1 )a n d
HOMA-IR (P = 0.011). Low anti-PC IgM- levels
occurred more often in patients (lowest tertile; P =
0.002; anti-PC determinations available in 111 SLE-cases
and 118 controls). There were no significant differences
in smoking, diabetes (few cases) or BMI.
In Table 2, SLE-patients and controls are compared
for atherosclerosis-related measurements. While IMT
and cIMa did not differ between groups, we determined
ad i f f e r e n c ei no c c u r r e n c eo f atherosclerotic plaques (P
= 0.029). Further, left-sided echoluscent plaques were
more prevalent in SLE as compared to controls (P <
0.016) but there was no significance at the right side.
CVD occurrence was increased in SLE (P <0 . 0 1 )w h e n
CVD was defined herein as a history of cerebrovascular
events, acute coronary syndrome (ACS), coronary artery
by-pass graft (CABG), heart valve prothesis/impairment,
peripheral arterial surgery or claudication.
In Table 3, SLE-patients with or without plaques are
compared. In univariate analysis, age (P <0 . 0 0 1 ) ,S L E
duration (P = 0.025), hypertension (P = 0.014), fasting
glucose-level (P = 0.001) but not HOMA insulin resis-
tance, LDL-cholesterol (P < 0.001), total cholesterol (P <
0.001), apoB/apoA1 (P = 0.004), BMI (P = 0.032), and
anti PC-levels (as determined both as low vs high levels
and as continuous values) were significantly different
between SLE-patients with and without plaques. The
total intake of glucocorticoid medications was not asso-
ciated with atherosclerotic plaques.
I nam u l t i v a r i a t ea n a l y s i sw ei n c l u d e do n l yf a c t o r si n
the model which were independently associated with
plaque prevalence in preceding univariate analyses.
Furthermore, if the same type of interrelated factors
were univariately associated, only the strongest was
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Cases Controls P-level
Number 114 122
Age. year 47.94 ± 13.17 49.11 ± 12.68 0.45
Male gender, % (no.) 12.28% (n = 14) 10.65% (n = 13) 0.94
Current smokers,% (no.) 14.03% (n = 16) 15.57% (n = 19) 0.47
Presence of diabetes,% (no) 5.26% (n = 6) 2.45% (n = 3) 0.22
Presence of hypertension, % (no.) 57.89% (n = 66) 26.22% (n = 32) <0.001
LDL>3 mmol/L,% (no.) 27.19% (n = 31) 44.26% (n = 54) 0.006
Current statins,% (no.) 10.52% (n = 12) 4.09% (n = 5) 0.048
Total cholesterol, mmol/L 4.7 ± 1.1 4.8 ± 1.0 0.23
LDL, mmol/L 2.5 ± 0.88 2.8 ± 0.80 0.026
HDL, mmol/L 1.6 (1.3 to 1.8) 1.6 (1.3 to 1.9) 0.31
Triglycerides, mmol/L 0.99 (0.7 to 1.4) 0.78 (0.55 to 1.10) 0.003
CRP, mg/L 4.44 (0.8 to 4.8) 2.04(0.5 to 2.5) <0.001
Apolipoprotein E 42.69 ± 14.7 38.84 ± 12.05 0.033
ApoB/ApoA1 0.55 (0.50 to 0.70) 0.60 (0.50 to 0.70) 0.39
BMI (kg/m2) 24.89 (20.96 to 27.85) 24.67 (22.41 to 27.82) 0.58
HOMA IR 1.34 (0.80 to 1.96) 1.05 (0.69 to 1.48) 0.011
IgM antiPC. U/ml 61.28 (36.44 to 176.06) 93.74 (52.90 to 134.22) 0.025
IgG antiPC. U/ml 9.36 (5.45 to 14.76) 7.45 (4.62 to 11.66) 0.0083
IgM antiPC < = 10
th percentile (%) 16.5% 2.8% < = 0.0005
IgM antiPC < = 25
th percentile (%) 32.1% 17.9 0.016
IgM antiPC < = 33th percentile (%) 42.0% 22.6% 0.0022
anti-PC, antibodies against PC; CR, C-reactive protein; HDL, high density lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL, low density
lipoprotein; PC, phosphorylcholine.
Table 2 Cardiovascular measurements in SLE-patients and controls
Cases Controls P-level
IMT R, mm 0.60 ± 0.13 0.62 ± 0.13 0.27
IMT L, mm 0.59 (0.50 to 0.71) 0.60 (0.52 to 0.70) 0.62
Plaque,% (no.) 42.98% (n = 49) 30.32% (n = 37) 0.029
cIMarea R, mm
2 11.39 (9.60 to 14.34) 11.90 (9.9.93 to 14.01) 0.51
cIMarea L, mm
2 11.81 (9.41 to 13.43) 11.64 (9.88 to 13.83) 0.78
Low-echogenic plaques (grade 1) left and right carotid artery 44 31 0.0962
Low-echogenic plaques (grade 1) left carotid artery 25 13 0.016
Low-echogenic plaques (grade 1) right carotid artery 19 18 0.62
Plaque distribution* Plaque 0 = 62 (54.38%) Plaque 0 = 85 (69.67%) 0.015
Plaque 1 = 20 (17.54%) Plaque 1 = 20 (16.39%) 0.74
Plaque 2 = 29 (25.43%) Plaque 2 = 17 (13.93%) 0.019
History of cerebrovascular events 7.89% (n = 9) 0.81% (n = 1) 0.007
History of AMI 4.38% (n = 5) 0 0.025
History of CABG 2.63% (n =3 ) 0 -
History of heart valve prothesis/impairmeant 9.64% (n = 11) 0.81% (n = 1) 0.002
History of peripheral arterial surgery 1.75% (n =2 ) 0 -
Claudication 8.77% (n = 10) 0.81% (n = 1) 0.003
CVD** 21.92% (n = 25) 2.45% (n = 3) < 0.001
*Plaque 0, no plaque; Plaque 1, plaque on one side; Plaque 2, plaque on both sides.
**Either of history of: cerebrovascular events, AMI, CABG, heart valve prothesis/impairment, peripheral arterial surgery, claudication.
AMI, acute myocardial infarction; CABG, coronary artery by-pass graft; cIMa, calculated intima-media area; CVD cardiovascular disease; IMT, common carotid
intima-media thickness.
Anania et al. Arthritis Research & Therapy 2010, 12:R214
http://arthritis-research.com/content/12/6/R214
Page 4 of 8included. As indicated in Table 4, only age, hyperlipide-
mia (LDL > 3 mmol/L) and anti-PC IgM (below lowest
tertile) remained significant and independently asso-
ciated with plaque occurrence.
If patients with previous CVD are excluded, the asso-
ciations between low anti-PC and plaque prevalence
remain significant (OR 4.4, CI 1.34 to 14.88, P= 0.029).
Discussion
We here report that patients with SLE from a novel
cohort in Huddinge, Southern Stockholm had an
increased number of carotid atherosclerotic plaques as
compared to sex- and age-matched controls from the
same area. However, common carotid IMT and cIMa
did not differ between groups. The observation of
increased occurrence of atherosclerotic plaques is in
accord with other, recent observational and/or prospec-
tive studies [2,20] and controlled studies [4,28], where
increased atherosclerosis has been reported as a feature
in SLE.
The somewhat surprising finding that plaque occur-
rence but not IMT or cIMa is increased in SLE is in
line with a previous publication where IMT was even
decreased in SLE [4]. Furthermore, in the present study
patients with SLE had echolucent plaques more often
than controls in the left carotid artery. Carotid
Table 3 Comparison between SLE patients with and without atherosclerotic plaques
SLE patients
With plaque
(n = 49)
Without plaque
(n = 62)
P
Age, years 55.79 ± 9.23 41.7 ± 12.76 < 0.001
Disease duration, mean 14.00 years 9.82 years 0.025
Current smokers, % (no.) 7.2% (n = 8) 6.3% (n = 7) 0.44
Presence of hypertension,% (no.) 31.5% (n = 35) 27% (n = 30) 0.014
Presence of diabetes,% (no.) 4.5% (n = 5) 0.9% (n = 1) 0.047
HOMA IR 1.41 (0.91 to 1.94) 1.20 (0.73 to 1.94) 0.41
Glucos (mmol/L) 4.70 (4.30 to 5.00) 4.35 (3.90 to 4.70) 0.0013
LDL(mmol/L) 2.87 ± 1.05 2.28 ± 0.66 0.001
Hyperlipidemia (LDL > 3) 38.77 (n = 19) 19.35 (n = 12) 0.023
Kolesterol (mmol/L) 5.05 ± 1.26 4.35 ± 0.98 0.001
ApoB/ApoA1, median 0.60 (0.50 to 0.80) 0.50 (0.45 to 0.60) 0.004
High sensitivity CRP, mg/l 1.85 (0.82 to 4.05) 1.75 (0.69 to 4.8) 0.980
Triglicerides (mmol/L) 1.00 (0.74 to 1.50) 0.94 (0.61 to 1.30) 0.065
BMI (kg/m2) 25.95 (22.28 to 28.41) 24.16 (20.08 to 26.84) 0.032
SLAM 6.00 (5 to 9) 6.50 (4 to 10) 0.41
SLEDAI 2 (0 to 5) 2 (0 to 6) 0.46
SLICC 1 (0 to 4) 1(0 to 2) 0.39
Lupus anticoagulans 10.81% (n = 12) 14.41% (n = 16) 0.87
Anticardiolipin Ab 8.18% (n = 9) 11.81% (n = 13) 0.70
Beta 2 glycoprotein 1 15.45% (n = 17) 18.18% (n = 20) 0.83
Cumulative lifetime glukocorticoid dose/year (g/year) 2.49 (1.75 to 3.68) 2.59 (1.87 to 3.49) 0.952
Glucocorticoid last year, gram 0.9 (0 to 2.19) 1.8 (0.07 to 2.70) 0.093
Chloroquin/hydroxychlorochine 42.85% (n = 21) 54.83% (n = 34) P = 0.210
IgM antiPC 48.75 (25.79 to 104.78) 85.94 (50.02 to 231.52) P = 0.001
IgM antiPC < = 10
th percentile (%) 23.40 10.17 0.0651
IgM antiPC < = 25
th percentile (%) 40.43 23.73 0.0651
IgM antiPC < = 33
th percentile (%) 57.45 28.81 0.0030
anti-PC, antibodies against PC; CR, C-reactive protein; HDL, high density lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL, low density
lipoprotein; PC, phosphorylcholine; SLAM, Systemic Lupus Activity Measure; SLEDAI, Systemic Lupus Erythematosus diseases activity index; SLICC, Systemic Lupus
International Collaborating Clinics damage index.
Table 4 Multiple regression analysis in relation to
occurrence of atherosclerotic plaques in SLE
Explanatory variable OR 95% CI P-value
Age 7.443 2.45122.602 0.0004
Hypertension 1.484 0.527 4.176 0.4550
Hyperlipidemia (LDL > 3 mmol/l) 5.012 1.511 16.624 0.0084
Glucose 2.299 0.886 5.964 0.0869
IgM anti-PC < = 51.19 2.920 1.080 7.895 0.0348
anti-PC, antibodies against phosphorylcholine; LDL, low density lipoprotein.
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vulnerable atherosclerotic lesions than echogenic pla-
ques [29]. Thus, individuals with carotid stenoses and
echolucent plaques were reported to have an increased
risk of stroke and cerebrovascular events compared with
individuals with stenoses and more echogenic plaques
[30]. The reason for the increased occurrence of echolu-
cent plaques on the left but not on the right side in
SLE-patients is not clear. However, a difference between
the left and right side concerning carotid atherosclerosis
has been reported previously. Thus, in one study of bor-
derline hypertension we found a significantly thicker
intima-media on the left than on the right side [26].
This observation has been confirmed by others [31,32].
Our present and previous findings raise the possibility
that atherosclerotic lesions develop in different pace and
mode in the left and right carotid arteries, possibly
because of the difference in gross anatomy of the left
and right CCA which might create different shear stress
conditions. Shear stress has been shown to be related to
both intima-media thickness and echogenecity [33].
Another explanation for the observed side differences is,
of course, that they may be a result of chance.
We here report that low levels of natural IgM anti-PC
antibodies are more prevalent in a cohort of SLE-patients
as compared with controls. We recently reported similar
findings in a nested case-control study, where SLE patients
with CVD were compared to those without CVD and with
controls [34], and in this study, low anti-PC IgM was
reported in line with our present observation [34]. We
also noted that anti-PC IgG was higher in SLE-patients
than in controls in the present study, which did not accord
with our previous data [34]. However, the studies differ in
important ways. Our previous study was designed to
determine risk factors of CVD and not atherosclerosis,
and was designed as a nested-case control study, where
SLE-cases with CVD were the basis of selection. Thus, the
age was much higher in this study, and there were no
male SLE-patients. It should be emphasized that prospec-
tive studies (and further experimental studies) are needed
to establish a mechanistic role for anti-PC IgG (and IgM),
and it is possible that the role of especially anti-PC IgG
may differ in different stages of disease. Of note, anti-PC
IgM appears to be more important for atherosclerosis
than IgG [13]. It is furthermore possible that there may be
important differences between the adaptive immune
response, which is commonly of IgG isotype, and the nat-
ural immune response, as represented by anti-PC IgM.
Whether dysregulation of natural immunity in SLE where
anti-PC IgM (which are anti-inflammatory [34]) could
play a role in the pathogenesis of SLE is an interesting
possibility which deserves further study.
Anti-PC IgM was negatively but non-significantly
associated with SLICC, and larger studies are needed to
establish whether such an association is significant and
could play a role in SLE.
We recently reported in different population-based
cohorts that low IgM anti-PC is an independent and
novel risk marker for development of cerebro- and car-
diovascular disease in the general population [14-16]
and also that it could predict death in uremic patients
treated with hemodialysis [35]. Thus, low anti-PC IgM
could represent an immune deficient state, predisposing
to CVD and in principle also to SLE, since anti-PC has
anti-inflammatory properties, inhibiting inflammatory
phospholipids as platelet activating factor [34]. Interest-
ingly, the strongly pro-inflammatory lipid mediator PAF
is implicated in active SLE [18] and a decreased capacity
to inhibit such effects could predispose to symtoms of
SLE or SLE itself.
Further, we demonstrated that human anti-PC inhibit
uptake of oxLDL in macrophages, implying another
non-mutually exclusive possible mechanism by which
anti-PC IgM could be atheroprotective [15].
While information about the role of natural antibodies
as anti-PC in humans and in clinical conditions has been
scarce, more is known in mice-models, where anti-PC
IgM protect against lethal meningococcal infections [36].
We reported that IgM anti-PC levels are higher in a
population from New Guinea than among Swedish age-
and sex-matched controls. These individuals live a tradi-
tional life as horticulturalists where CVD rheumatic
diseases appear to be rare, a finding that is not likely to
be caused by a decreased life expectancy in adulthood
[37]. We hypothesized that this may contribute to their
low incidence of CVD, in addition to more favourable
metabolic and other risk factors, except smoking, sur-
prisingly enough. Diet factors and exposure to infectious
agents including nematodes and parasites may contri-
bute, but the reasons for differences in anti-PC levels
among cohorts are not well understood [38]. The possi-
bility that diet factors contribute to anti-PC levels is
supported by our recent findings in patients with rheu-
matoid arthritis, where a gluten-free vegan diet included
an increase [39], which was also the case in another
study where patients on a self-reported Mediterranean
diet had raised levels [40]. It is also possible that anti-
PC levels are influenced by consumption into tissue, for
example because of increased apoptosis and thus bind-
ing of anti-PC.
Among traditional risk factors, hypertension and
increased triglycerides was significantly more common
in SLE, while smoking was not, which in general is in
line with previous observations [3,5]. LDL is not known
to be commonly raised in SLE, and in this study, the
frequency of hyperlipidemia was even higher among
controls. An interesting finding is that HOMA, a mea-
sure of insulin resistance, was increased in SLE. This
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that SLE in general is characterized by early metabolic
changes.
Within the SLE group, plaque occurrence was inde-
pendently associated with age and LDL (positively) and
negatively with anti-PC IgM. This finding is in accor-
dance with our previous study where we reported a
negative association between IgM anti-PC and athero-
sclerosis development in hypertensives [13]. Thus, tradi-
tional risk factors in combination with low levels of
anti-PC IgM may explain the observed increased occur-
rence of plaques in SLE as observed in the present
study.
Cumulative or present doses of prednisolone (or corti-
costeroids) were not associated with the occurrence of
atherosclerotic plaques. Prednisolone has been much
discussed in rheumatic disease and has often been
described as pro-atherogenic due to its unfavourable
effects on metabolic factors. However, we recently
reported that in rheumatoid arthritis, there is no asso-
ciation between prednisolone intake and atherosclerosis
development [42]. Our present data argue against the
possibility that prednisolone is proatherogenic in SLE. It
is possible that the anti-inflammatory effects of corticos-
teroids are more important than the negative influence
on lipids in relation to atherosclerosis [43].
Conclusions
Taken together, our data indicate that atherosclerotic
plaques, but not general atherosclerosis as indicated by
IMT measurements, are more prevalent in SLE as com-
pared to controls. Further, vulnerable atherosclerotic
plaques are more common in SLE. Age, LDL and low
levels of anti-PC IgM are independently associated with
the prevalence of atherosclerotic plaques in SLE.
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